Literature DB >> 15812486

T cell vaccines for microbial infections.

Harriet L Robinson1, Rama Rao Amara.   

Abstract

Vaccination, or the deliberate induction of protective immunity by administering nonpathogenic forms of a microbe or its antigens to induce a memory immune response, is the world's most cost-effective medical procedure for preventing morbidity and mortality caused by infectious disease. Historically, most vaccines have worked by eliciting long-lived plasma cells. These cells produce antibodies that limit disease by neutralizing a toxin or blocking the spread of the infectious agent. For these 'B cell vaccines,' the immunological marker, or correlate, for protection is the titer of protective antibodies. With the discovery of HIV/AIDS, vaccine development has been confronted by an agent that is not easily blocked by antibody. To overcome this, researchers who are developing HIV/AIDS vaccines have turned to the elicitation of cellular immunity, or 'T cell vaccines,' which recognize and kill infected cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15812486     DOI: 10.1038/nm1212

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  87 in total

Review 1.  The role of mTOR in memory CD8 T-cell differentiation.

Authors:  Koichi Araki; Ben Youngblood; Rafi Ahmed
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine.

Authors:  Sunil Kannanganat; Pragati Nigam; Vijayakumar Velu; Patricia L Earl; Lilin Lai; Lakshmi Chennareddi; Benton Lawson; Robert L Wilson; David C Montefiori; Pamela A Kozlowski; Bernard Moss; Harriet L Robinson; Rama Rao Amara
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

3.  Manipulating Memory CD8 T Cell Numbers by Timed Enhancement of IL-2 Signals.

Authors:  Marie T Kim; Samarchith P Kurup; Gabriel R Starbeck-Miller; John T Harty
Journal:  J Immunol       Date:  2016-07-20       Impact factor: 5.422

4.  Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling.

Authors:  Asa S Hidmark; Eva K L Nordström; Pia Dosenovic; Mattias N E Forsell; Peter Liljeström; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Sculpting the immunological response to dengue fever by polytopic vaccination.

Authors:  Hao Zhou; Michael W Deem
Journal:  Vaccine       Date:  2005-12-28       Impact factor: 3.641

6.  Optimization of the delivery of heterologous proteins by the Salmonella enterica serovar Typhimurium type III secretion system for vaccine development.

Authors:  Li-Mei Chen; Gabriel Briones; Ruben O Donis; Jorge E Galán
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

Review 7.  Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivector.

Authors:  Yukai He; Louis D Falo
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

8.  A systematic bioinformatics approach for selection of epitope-based vaccine targets.

Authors:  Asif M Khan; Olivo Miotto; A T Heiny; Jerome Salmon; K N Srinivasan; Eduardo J M Nascimento; Ernesto T A Marques; Vladimir Brusic; Tin Wee Tan; J Thomas August
Journal:  Cell Immunol       Date:  2007-04-16       Impact factor: 4.868

9.  Recognition of escape variants in ELISPOT does not always predict CD8+ T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences.

Authors:  Laura E Valentine; Shari M Piaskowski; Eva G Rakasz; Nathan L Henry; Nancy A Wilson; David I Watkins
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

10.  Humoral and cellular immune responses to influenza vaccination in children with cancer receiving chemotherapy.

Authors:  Rosa María Wong-Chew; Margarita Nava Frías; Miguel Leonardo García-León; Lourdes Arriaga-Pizano; Aurora Medina Sanson; Constantino Lopez-Macías; Armando Isibasi; José Ignacio Santos-Preciado
Journal:  Oncol Lett       Date:  2012-05-17       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.